121 related articles for article (PubMed ID: 3720034)
21. Prognostic factors of diffuse proliferative lupus nephritis.
Lim CS; Chin HJ; Jung YC; Kim YS; Ahn C; Han JS; Kim S; Lee JS
Clin Nephrol; 1999 Sep; 52(3):139-47. PubMed ID: 10499308
[TBL] [Abstract][Full Text] [Related]
22. [Renal manifestations of systemic autoimmune disease: diagnosis and therapy].
O'Callaghan CA
Nephrol Ther; 2006 Jul; 2(3):140-51. PubMed ID: 16890139
[TBL] [Abstract][Full Text] [Related]
23. [Therapy of lupus nephritis in childhood].
Taubert M; Döring E
Padiatr Grenzgeb; 1983; 22(2-3):191-4. PubMed ID: 6888932
[No Abstract] [Full Text] [Related]
24. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
[TBL] [Abstract][Full Text] [Related]
25. Focal segmental lupus nephritis.
Grishman E; Churg J
Clin Nephrol; 1982 Jan; 17(1):5-13. PubMed ID: 7055995
[TBL] [Abstract][Full Text] [Related]
26. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.
Szeto CC; Kwan BC; Lai FM; Tam LS; Li EK; Chow KM; Gang W; Li PK
Rheumatology (Oxford); 2008 Nov; 47(11):1678-81. PubMed ID: 18753192
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
28. [Plasma exchange in rapidly progressive glomerulonephritis (author's transl)].
Glöckner WM; Dienst C; Kindler J; Sieberth HG
Dtsch Med Wochenschr; 1981 Nov; 106(48):1616-20. PubMed ID: 7308001
[TBL] [Abstract][Full Text] [Related]
29. [Plasma exchange therapy in children and adolescents with systemic lupus erythematosus (SLE)].
Pistor K; Neudorf U
Monatsschr Kinderheilkd; 1987 Jan; 135(1):47-50. PubMed ID: 3494196
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of emergency situations in autoimmune diseases with plasma exchange].
Samtleben W; Blumenstein M; Habersetzer R; Gurland HJ; Link F; Meurer M; Besinger UA
Acta Med Austriaca; 1982; 9(3):93-7. PubMed ID: 7148354
[TBL] [Abstract][Full Text] [Related]
31. Effect of treatment on the evolution of renal abnormalities in lupus nephritis.
Balow JE; Austin HA; Muenz LR; Joyce KM; Antonovych TT; Klippel JH; Steinberg AD; Plotz PH; Decker JL
N Engl J Med; 1984 Aug; 311(8):491-5. PubMed ID: 6749206
[TBL] [Abstract][Full Text] [Related]
32. Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange.
Krmar RT; Holtbäck U; Linné T; Berg UB; Celsi G; Söderberg MP; Wernerson A; Szakos A; Larsson S; Skattum L; Bárány P
Clin Nephrol; 2011 Feb; 75 Suppl 1():4-10. PubMed ID: 21269585
[TBL] [Abstract][Full Text] [Related]
33. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
Wang HY; Cui TG; Hou FF; Ni ZH; Chen XM; Lu FM; Xu FF; Yu XQ; Zhang FS; Zhao XZ; Zhao MH; Wang GB; Qian JQ; Cai GY; Zhu TY; Wang YH; Jiang ZP; Li YN; Mei CL; Zou WZ;
Lupus; 2008 Jul; 17(7):638-44. PubMed ID: 18625636
[TBL] [Abstract][Full Text] [Related]
34. "End-stage" lupus nephritis: clinical course to and outcome on dialysis. Experience with 39 patients.
Kimberly RP; Lockshin MD; Sherman RL; Beary JF; Mouradian J; Cheigh JS
Medicine (Baltimore); 1981 Jul; 60(4):277-87. PubMed ID: 7242321
[No Abstract] [Full Text] [Related]
35. Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma-exchanges. A prospective randomised study.
Rifle G; Chalopin JM; Zech P; Deteix P; Ducret F; Vialtel P; Cordonnier D
Proc Eur Dial Transplant Assoc; 1981; 18():493-502. PubMed ID: 7036171
[TBL] [Abstract][Full Text] [Related]
36. [Synchronizing therapy with plasmapheresis and cyclophosphamide in rapidly progressing systemic lupus erythematosis with kidney involvement].
Demin AA; Sentiakova TN; Smirnov VV; Demina LM; Mamin IV
Ter Arkh; 1996; 68(5):27-30. PubMed ID: 9082593
[TBL] [Abstract][Full Text] [Related]
37. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
Conlon PJ; Fischer CA; Levesque MC; Smith SR; St Clair EW; Allen NB; Fleming JA; Howell DN
Clin Nephrol; 1996 Sep; 46(3):170-5. PubMed ID: 8879851
[TBL] [Abstract][Full Text] [Related]
38. SLE with diffuse alveolar hemorrhage, microangiopathic hemolytic anemia and acute renal failure.
Yongsiri S; Thammakumpee J; Annanon N
J Clin Apher; 2012 Nov; 27(5):263-4. PubMed ID: 22730045
[TBL] [Abstract][Full Text] [Related]
39. [Successful treatment of allergic purpura nephritis associated with thrombotic microangiopathy using plasma exchange: a case report].
Kuwabara T; Ohnishi T; Kakuta Y; Nomura S; Joh K
Nihon Jinzo Gakkai Shi; 2004; 46(8):815-21. PubMed ID: 15645739
[TBL] [Abstract][Full Text] [Related]
40. The natural history and response to therapy of lupus nephritis.
Ginzler EM; Bollet AJ; Friedman EA
Annu Rev Med; 1980; 31():463-87. PubMed ID: 6994624
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
